Mark Cuban Adds Support to Break Up Big Medicine Act

Why It Matters

If enacted, the bill could dismantle entrenched monopolies, lower drug and service prices, and restore competition across the U.S. health‑care supply chain. It also signals escalating political and regulatory pressure on the nation’s largest health‑care conglomerates.

Key Takeaways

• Cuban publicly supports Senate bill targeting insurer-PBM integration
• Bill would force divestiture of non‑insurance subsidiaries
• Three PBMs control 80% of prescription claims
• 4,000 independent pharmacies closed since 2019
• DOJ investigating UnitedHealth’s Optum for antitrust concerns

Pulse Analysis

The Break Up Big Medicine Act, championed by Senators Elizabeth Warren and Josh Hawley, aims to dismantle the vertical integration that lets a single corporate parent control insurance, pharmacy‑benefit management and provider networks. Mark Cuban’s endorsement adds a high‑profile business voice to the debate, underscoring how conglomerate structures can inflate premiums and drug prices. By prohibiting insurers from owning PBMs or medical‑provider entities, the bill seeks to eliminate conflicts of interest that allow companies to steer patients toward in‑house services and extract higher reimbursements.

Concentration in the health‑care market has reached critical levels: three PBMs now process roughly 80% of prescription claims, and three drug wholesalers dominate 98% of distribution. This dominance has contributed to the closure of nearly 4,000 independent pharmacies since 2019 and pushed about 80% of physicians into corporate employment. Such market power reduces bargaining leverage for employers and consumers, driving up the cost of health benefits, which rank as the second‑largest expense for U.S. businesses after payroll.

Regulators are already moving. The Department of Justice’s antitrust probe into UnitedHealth’s Optum unit highlights growing scrutiny of integrated health‑care models. Should the bill pass, giants like CVS Health and UnitedHealth would be compelled to spin off pharmacy assets, reshaping the industry’s competitive landscape. Analysts anticipate that forced divestitures could spur new entrants, lower drug prices, and improve transparency, while also prompting insurers to re‑evaluate their service portfolios and cost‑containment strategies.